Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.

Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.

Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or...

These companies may perform well in any market environment.

Las acciones de Eli Lilly and Co. subieron a alrededor de 1.152 dólares a mediados de septiembre de 2026 cuando Berenberg elevó su precio.

Gwen Nichols: Thank you Eli Lilly and Company for Inviting to Speak at the Lilly Oncology University / blood cancer, cancer, Eli Lilly and Company, Eric

On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes. Analysts said Amgen’s olpasiran faces […]

Eli Lilly (NYSE:LLY) returns to the Healthcare Stocks conversation, with focus on product demand, regulatory milestones, pipeline execution, reimbursement, and operating discipline shaping the read on the business.

Eli Lilly (LLY) just put fresh clinical data at the center of its story, highlighting new results for obesity and diabetes drugs and a genetic medicine collaboration with QurCan Therapeutics. Recent price action has cooled a little, with a 30-day share price return that declined 3.83%, even as Eli Lilly’s stock still shows a 5.32% year-to-date share price gain and a very strong 1-year total shareholder return of 50.63%. This points to momentum that remains firmly positive over a longer...

On September 15, Berenberg upgraded its rating on Eli Lilly and Company (NYSE:LLY) from Hold to Buy and lifted its price target from $1,220 to $1,400. The research firm pointed to the company’s strong returns on investment and its growth in the obesity treatment market. Berenberg said its 2026 return on research investment analysis confirms […]

On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight, though far less than at full recommended doses, and experience less nausea. Patients on Eli Lilly and Company (NYSE:LLY)’s low-dose tirzepatide lost an average of 5.5% of their […]